FDA Approves DELSTRIGO — Merck Sharp & Dohme LLC

Merck Sharp & Dohme (MSD) announced the FDA approval of Brand DELSTRIGO, a single-tablet regimen combining doravirine, lamivudine, and tenofovir disoproxil fumarate, marking a notable expansion of the company's antiretroviral portfolio to provide an alternative oral therapeutic option for HIV-1 treatment. This launch is expected to capture market share from competitor integrase inhibitors due to its high potency and favorable resistance profile, placing it in direct competition with established single-pill regimens.